and ultrasound of the heart. Level 2 evidence was required in each domain to obtain a comparable system to TOAST (ASCO2). Clinical and biochemical characteristics and mortality rates were documented and compared by the two classification systems. Results: Of 142 patients consecutively evaluated and recruited in the study, a total of 101 ICVD patients (ischemic stroke, n = 84; transient ischemic attack, n = 17) were included in the final analysis. Agreement between ASCO2 and TOAST was very good. During the mean observation period of 28 months, 26 patients died. The 1-and 4-year mortality rates were 0 and 4% for large artery atherosclerosis (LAA); 23 and 36% for cardioembolism (CE); 0% for small artery occlusion (SAO); 63 and 100% for the subtype with unknown etiology due to incomplete workup (Unknown), and 12 and 29% for the cryptogenic subtype. As for the ASCO2 groups, the 1-and 4-year mortality rates were 0 and 6% in LAA, 25 and 36% in CE, 0% in SAO, 0 and 14% in LAA + CE, 0% in SAO + CE, 16 and 36% in the subgroup with undetermined etiology despite complete workup, and 56 and 100% in Unknown. Regression analysis showed that age, white blood cell count, fibrinogen and bilirubin, but not etiological subgroup, were independent predictors of mortality. Conclusion: Our findings indicate that clinical and biochemical markers may differentiate phenotypically homogeneous etiological subtypes and predict longterm mortality. Further studies with larger patient numbers are needed to investigate possible causative mechanisms. 
Introduction
Ischemic stroke (IS) and transient ischemic attack (TIA), together labeled as ischemic cerebrovascular disease (ICVD), is an etiologically heterogeneous disease with more than 150 known causes [1] . Unfortunately, 25-40% of all ischemic events remain classified as cryptogenic, when no potential mechanism is detected despite extended investigation with all available diagnostic tools [2] . Identification of the specific cause in every patient has important clinical implications, because prognosis, acute management, and long-term strategies to prevent recurrences may vary considerably for the different types of ICVD. Stroke has caused 5.7 million deaths in 2005 and is projected to 6.7 million deaths in 2015 worldwide [3] . Therefore collecting information regarding factors related to prognosis and mortality may improve stroke care both in the short and long term.
Previous studies on IS have shown different rates of mortality, probably owing to heterogeneous groups of patients [4] . In 1993, in order to create a uniform approach to determine the subtypes of IS, the investigators of the Trial of Org 10172 in Acute Stroke Treatment (TOAST) developed an etiological classification system based on the results of diagnostic tests, the absence or presence of risk factors and clinical findings [5] . One argued shortcoming of this classification system is that patients having at least two definite potential causes are grouped together with those having an entirely negative workup. By merging different phenotypes in one group, a major bias is introduced in clinical studies that aim to investigate risk factors or genetic associations. The ASCO classification system introduces a new approach that defines clinically and pathogenically meaningful groups [6] . It recognizes that many patients belong to several categories, some of which may be causally associated with the index stroke, whereas others are simply concurrent. A recent Irish study showed excellent agreement between ASCO and TOAST schemes, although each had specific characteristics for subtype assignment and data retention [7] . Shang and Liu [8] indicated moderately high agreement between ASCO and TOAST in all subtypes except that of undetermined etiology. In young stroke patients, the use of ASCO criteria showed more cases of undetermined and less cardioembolic etiology compared to TOAST, reflecting uncertainty regarding the pathogenic relevance of patent foramen ovale in the age group <55 years [9] .
Conventional risk factors such as atherosclerosis, hypertension and obesity may overlap among different etiological subtypes of ICVD [10] and share common systemic inflammatory profiles [reviewed in ref . 11 ] . Studies on biochemical markers differentiating ICVD etiological subtypes report elevated tumor necrosis factor-α, interleukin-6 and interleukin-1β [12] , D-dimer, and fibrinogen in cardioembolic stroke, and high levels of erythrocyte sedimentation rate and fibrinogen in atherothrombotic stroke [12, 13] .
Here, introducing the Acute Inflammatory Stroke Study (AISS), a hospital-based cohort described by TOAST and ASCO classification systems, mortality rates are investigated in relation to stroke etiology, and clinical and biochemical markers.
Methods

Participants
The Karolinska University Hospital in Huddinge is a hospital of reference with approximately 800 beds, serving an ethnically diverse population of around 250,000. AISS is a prospective hospital-based cohort, initially designed to investigate the role of inflammatory parameters on clinical outcome after acute IS or TIA. Inclusion and exclusion criteria of the study are presented in online supplementary table 1 (for all online suppl. material, see www. karger.com/doi/10.1159/000346094). All patients were evaluated by the study investigators with clinical examination and biochemical analysis of blood samples at admission (as reported in online suppl. table 2) and at follow-up on day 2, day 7 or earlier if exit of the stroke unit, 1 month, 3 months and 12 months after stroke. Of 142 patients consecutively evaluated and recruited in the study, between May 2006 and May 2010, 101 were included in the final analysis.
Data Collection and Clinical Variables
The evaluation of all patients at admission included collection of demographic data, medical history, vascular risk factors, National Institute of Health Stroke Scale (NIHSS) score upon admission, modified Rankin Score before the ischemic event and biochemical test results. Follow-up visits were scheduled in-hospital while at the stroke unit, at 2 and 7 days from symptom onset and in the outpatient ward at 1 month, 3 and 12 months after ICVD. The follow-up evaluation was performed by the study investigators (the same investigator followed each patient), and included clinical and functional evaluation by NIHSS, modified Rankin Score and Barthel Index, measurement of blood pressure and body temperature and laboratory tests. Information on date of death was available in electronic records for all deceased patients.
All patients underwent computed tomography (CT) and/or magnetic resonance tomography of the brain. To identify the potential mechanism of cerebral infarction, electrocardiography (ECG), chest echocardiography, carotid ultrasonography, complete blood count and blood biochemistry were performed in all patients. When indicated, some patients also underwent magnetic resonance, CT and/or digital subtraction angiography, transesophageal echocardiography, Holter monitoring and special anticoagulation tests. 
IS Classification
A physician reviewing original imaging and medical histories classified the patients into five subtypes according to TOAST criteria: large artery atherosclerosis (LAA), cardioembolism (CE), small artery occlusion (SAO) and stroke of undetermined etiology. Other determined stroke etiology was not included in the study. The undetermined group was further divided into cryptogenic (CRYPT), which comprised cases with no cause found despite appropriate investigation and 1 patient with two causes identified, and unknown due to incomplete workup (Unknown). Complete workup according to ASCO comprised CT or MRI of the head, ECG, duplex of the extracranial arteries or CT/MR angiography and ultrasound of the heart. Level 2 evidence was required in each domain, to obtain a comparable system to TOAST (ASCO2). Phenotypic classification according to ASCO2 generated seven groups: LAA pure, CE pure, SAO pure, LAA + CE, SAO + CE, undetermined etiology despite complete workup (Neg Wup) and Unknown. Pure phenotypes included patients with grade 1 or 2 of one pathology and grade 0, 3 or 9 for the remaining ones. Mixed phenotypes included patients with grade 1 or 2 of two pathologies. There were no patients with all the three pathologies present.
Risk Factors
Arterial hypertension was considered present when the patients were on antihypertensive treatment upon admission, or when hypertension was diagnosed by repeated measurements of systemic blood pressure >140/90 mm Hg during hospital stay. Diabetes mellitus was considered present when patients had a known diagnosis, and/or were on antidiabetic treatment upon admission or had a fasting HbA Ic value ≥ 6.5%. Hyperlipidemia was defined by the presence of statin treatment upon admission or fasting total cholesterol ≥ 5.2 mmol/l or LDL cholesterol ≥ 2.6 mmol/l. Atrial fibrillation was considered present when mentioned in patients' past medical history or present at admission ECG. Heart failure and angina were considered present when mentioned in patients' medical history. All patients smoking any kind of tobacco on a daily basis were coded as smokers, while former smokers of at least 3 months without smoking were coded as nonsmokers.
Data Analysis
Differences in continuous variables among groups were investigated by the Mann-Whitney and Kruskal-Wallis tests, and categorical variables were analyzed using the Fisher's exact test. Agreement between classification systems was measured using the κ statistic, with values interpreted as good (0.61-0.8) or very good (0.81-1) [14] . Survival analysis was performed with the KaplanMeier method and log-rank test was implemented to assess for statistically significant differences in survival among stroke groups. Cox proportional hazards regression analysis was performed to identify predictors of survival. Multiple tests correction was not performed due to the exploratory purpose of the study. Stata/IC 12 for Windows, 2011 (College Station, Tex., USA; StataCorp LP) was used for all statistical analyses.
Results
Study Population
A total of 101 patients were included in the final analysis. IS was confirmed in 84 patients (83%) based on imaging data and 17 patients (17%) were classified as TIA due to regression of symptoms within 24 h.
Demographic, risk factor and clinical investigation profiles of the cohort are presented in table 1 . Patients with TIA were younger and in higher proportion male than those with IS. Extra-and intracranial vascular imaging was performed to a greater extent in TIA than IS patients. Conventional vascular risk factors including hypertension, diabetes mellitus, atrial fibrillation, heart failure, angina, hyperlipidemia and current smoking did not differ between stroke and TIA.
Etiological Classification
According to TOAST, patients were assigned to LAA (n = 26), CE (n = 40), SAO (n = 9), CRYPT (n = 18) and Unknown due to incomplete workup (n = 8). ASCO2 generated seven groups: LAA pure (n = 18), CE pure (n = 36), SAO pure (n = 8), LAA + CE (n = 12), SAO + CE (n = 5), Neg Wup (n = 13) and Unknown (n = 9). The overlap of matching groups is presented in the Venn diagrams of figure 1 . Neg Wup by ASCO was matched to CRYPT by TOAST.
Differences in risk factor and clinical chemistry profile among phenotypic groups at admission were examined separately by ASCO2 and TOAST (online suppl. table 2), and a subgroup analysis comprising only pure phenotypic groups by ASCO2 was also performed. By TOAST, patients with CE were older than those with LAA and SAO. In ASCO2, hypertension was less common in SAO pure (25%) and Unknown (33%) compared to mixed phenotypes (82%), and intermediate frequencies were reported in LAA pure (50%) and CE pure (54%). Hyperlipidemia was less common in Unknown by both ASCO2 (44%) and TOAST (38%), and most common in mixed phenotypes (94%) by ASCO2. White blood cell count and bilirubin levels were highest in Unknown followed by CE and LAA, and were lowest in SAO. Fibrinogen values were low in SAO and higher in Unknown. High iron and low urea levels were measured in SAO patients compared to CE and Unknown (online suppl. table 2). Subgroup analysis in pure ASCO2 phenotypic groups indicated differences in white blood cell count, fibrinogen, iron and urea levels (p = 0.05, 0.04, 0.006 and 0.01, respectively). Total cholesterol and LDL cholesterol were also different among pure phenotypic ASCO2 groups (p = 0.06 and 0.03, respectively), and this was not seen when all ASCO2 groups were included in the same model.
Survival Analysis
During the mean observation period of 28 months, 26 patients died. Of all deaths, 13 were attributed to the cerebrovascular event, 7 to heart disease, 3 to nonvascular causes and 3 to unidentified cause of death. Four of these 26 patients died within 30 days. The overall mortality rate at 1 month after symptom onset was 0% in LAA and SAO by TOAST, and 18, 6 and 50% in CE, CRYPT and Unknown, respectively. The 1-and 4-year mortality rates were 0 and 4% in LAA; 23 and 36% in CE; 0% in SAO; 63 and 100% in Unknown, and 12 and 29% in CRYPT ( fig. 2 a, p < 0 .0001, by log-rank test). As for the ASCO2 groups, the 1-and 4-year mortality rates were 0 and 6% in LAA, 25 and 36% in CE, 0% in SAO, 0 and 14% in LAA + CE, 0% in SAO + CE, 16 and 36% in Neg Wup, and 56 and 100% in Unknown ( fig. 2 b, blood cell count, fibrinogen and bilirubin were included in the final model. The model was adjusted for severity of stroke as indicated by NIHSS score at admission. Hazard ratios are presented in table 2 . After stratification for the TOAST and ASCO2 groups, fibrinogen did not remain in the model (p = 0.2 and 0.1, respectively, not shown).
Discussion
Our first analysis of AISS delineates the biochemical profile and long-term survival in a hospital-based cohort of 101 ICVD patients, classified according to TOAST and ASCO2. Survival rates were higher in SAO, in both classification systems, and worse in CE and Unknown. Age, white blood cell count, fibrinogen and serum bilirubin, yet not etiology itself, were independent predictors of 4-year mortality.
The ASCO classification system has been suggested to provide better-described, phenotypically homogeneous groups, and thereby be more useful in clinical studies [6] . In our study, the greatest discrepancy was observed within the LAA group, which was more heterogeneous as defined by the TOAST scheme including mixed phenotypes. Still, the κ value indicated good agreement of the two systems. The remaining subtypes had κ values over 0.81, indicating very good agreement between classification systems. Mixed phenotypes generated two groups with CE coexisting with LAA and SAO, respectively. No patient had all three phenotypes, nor combined LAA and SAO. This may be due to no further investigation with MRI, in cases with enough evidence validating LAA as causative mechanism.
In agreement with previous, larger hospital-based studies [15] , the major cause of death was the index cerebrovascular event, followed by heart disease. One-month mortality rate was 4%, somewhat lower than previously reported rates of a population-based survey of southern Sweden [16] . Among etiological subtypes, long-term mortality has been reported to be highest in CE, followed by patients with IS of uncertain etiology, lacunar infarction and large-vessel disease, in a large population-based study [17] . Here, we describe the highest mortality rates in patients with Unknown, followed by those with CE, negative workup, SAO and LAA. Also, stroke subtype was not confirmed to be an independent predictor of survival when pure phenotypes were examined. This is not coherent with previous studies using TOAST, reporting unknown etiology and CE as independent predictors of mortality [4, 18] . This discrepancy between mixed and pure phenotypes may indicate the presence of other factors in addition to the etiological mechanism itself that may contribute to 218 mortality risk. The poor survival rate in patients with unknown etiology due to incomplete workup may be associated with advanced age and severity of stroke, which interfered with extensive clinical investigation. Elderly IS patients received less intensive stroke management, which together with poor health and prestroke disability contributes to poorer clinical outcome [19] . Circulating inflammatory markers, including C-reactive protein, interleukin-6, fibrinogen and white blood cell count have been associated with increased risk for recurrent vascular events and all-cause mortality 2 years after IS [20] . In our study, fibrinogen and white blood cell count at admission were associated with increased mortality rates in ICVD, after adjustment for age and stroke severity. High levels of fibrinogen, together with D-dimer, have also been correlated to cardioembolic stroke [13] . Here, the highest fibrinogen levels were found in Unknown, followed by CE, which may reflect a number of undiagnosed sources of CE in the Unknown group.
Our results, although with marginal statistical significance, indicate a direct association between bilirubin levels at admission and mortality rates. Presence of transient hyperbilirubinemia has been reported during the acute phase of IS [21] , and elevated bilirubin levels have been associated with greater stroke severity but not outcome, possibly reflecting the intensity of initial oxidative stress [22] . In acute stroke, transient cholestasis is associated with deeper coma, autonomic and hypothalamic involvement and common bile duct dilatation without obstruction [23] . High bilirubin levels in Unknown may reflect the severity of stroke in this subgroup of older age and high mortality rates. In healthy individuals, serum bilirubin has consistently shown to be inversely related to cardiovascular disease due to its antioxidative effect [24] . In a population-based survey, higher serum total bilirubin levels were associated with lower stroke incidence and improved functional outcome [25] . Less is known about the possible effect of bilirubin in cardiovascular and allcause mortality after IS.
The main limitation of the study was the small number of patients included, resulting in limited power for the investigation of phenotypic subgroups. However, subgroup analysis has been performed, and presented survival rates and predictors of survival show acceptable robustness, and are coherent to previous studies. The fact that IS and TIA patients have been investigated together may lead to false lower mortality rates, but it does not interfere with the main scope of the study to describe the profiles of phenotypically homogeneous subgroups. Mortality rates may be of minor clinical concern to correlate with stroke etiology, but add complementary information to the description of phenotypes. The differences in clinical and biochemical variables among groups are presented uncorrected for multiple testing. This part of the analysis should thereby be considered inadequate for causal associations, but valuable as part of the description of our population; κ values and the level of agreement between classification systems should be interpreted with caution while keeping in mind the small size of each group.
Our findings may indicate that fibrinogen, white blood cells and bilirubin could predict long-term mortality in ICVD, independent of etiology. Future studies on larger populations would enable the investigation of possible causative mechanisms serving as targets for improving prognosis.
